Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined.
作者信息
Chouaïd Christos, Baize Nathalie, Monnet Isabelle
机构信息
Univ Paris Est Créteil, INSERM, IMRB, Equipe CEpiA, 94010 Créteil, France.
Service de Pneumologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
出版信息
Transl Lung Cancer Res. 2020 Oct;9(5):1732-1735. doi: 10.21037/tlcr-20-362.
Abstract
摘要
相似文献
1
Second-line therapy for disseminated small-cell lung cancer: optimal management remains to be defined.播散性小细胞肺癌的二线治疗：最佳管理仍有待确定。
Transl Lung Cancer Res. 2020 Oct;9(5):1732-1735. doi: 10.21037/tlcr-20-362.
2
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.铂类双联化疗二线治疗复发性小细胞肺癌患者的系统评价和荟萃分析。
Lung Cancer. 2021 Jun;156:59-67. doi: 10.1016/j.lungcan.2021.04.013. Epub 2021 Apr 19.
3
Management and outcomes of non-small cell lung cancer patients with rapid progression under second-or-more-line immune checkpoint inhibitors: ERORECI study (GFPC 2016-04).二线或以上免疫检查点抑制剂治疗下快速进展的非小细胞肺癌患者的管理和结局：ERORECI 研究（GFPC 2016-04）。
Cancer Med. 2020 Jan;9(2):432-439. doi: 10.1002/cam4.2716. Epub 2019 Nov 20.
4
Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.二线治疗的老年晚期非小细胞肺癌患者中，严重不良事件影响总体生存和成本。
Lung Cancer. 2018 May;119:112-119. doi: 10.1016/j.lungcan.2018.02.011. Epub 2018 Feb 21.
5
Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?在晚期非小细胞肺癌中是否存在最佳治疗顺序？
Expert Opin Pharmacother. 2008 Jun;9(8):1321-37. doi: 10.1517/14656566.9.8.1321.
6
Chemotherapeutic management of stage IV non-small cell lung cancer.IV期非小细胞肺癌的化疗管理
Chest. 2003 Jan;123(1 Suppl):226S-243S. doi: 10.1378/chest.123.1_suppl.226s.
7
Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.老年复发性小细胞肺癌患者接受二线化疗的生存及预后因素：日本肺癌登记联合委员会的结果
Lung Cancer. 2020 Aug;146:160-164. doi: 10.1016/j.lungcan.2020.05.038. Epub 2020 Jun 6.
8
Optimal drugs for second-line treatment of patients with small-cell lung cancer.小细胞肺癌患者二线治疗的最佳药物。
Expert Opin Pharmacother. 2016;17(7):969-76. doi: 10.1517/14656566.2016.1154539. Epub 2016 Feb 29.
9
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).表皮生长因子受体（EGFR）突变阳性的晚期非小细胞肺癌患者一线吉非替尼治疗后化疗的疗效——一项比较吉非替尼与卡铂加紫杉醇的随机III期研究（NEJ002）的数据
Jpn J Clin Oncol. 2015 Jul;45(7):670-6. doi: 10.1093/jjco/hyv054. Epub 2015 Apr 15.
10
Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.日本晚期或复发性非小细胞肺癌的系统治疗模式：一项回顾性医院管理数据库研究
Clin Ther. 2017 Jun;39(6):1146-1160. doi: 10.1016/j.clinthera.2017.04.010. Epub 2017 May 18.
引用本文的文献
1
FOXM1 targeting alters AURKB activity and reshapes antitumor immunity to curb the progression of small cell lung cancer.靶向FOXM1可改变AURKB活性并重塑抗肿瘤免疫以抑制小细胞肺癌进展。
Res Sq. 2025 Jul 1:rs.3.rs-6960266. doi: 10.21203/rs.3.rs-6960266/v1.
2
Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer.纳米白蛋白结合型紫杉醇联合吉西他滨治疗复发/难治性小细胞肺癌的II期研究
Front Oncol. 2024 Jul 31;14:1303268. doi: 10.3389/fonc.2024.1303268. eCollection 2024.
3
Combined PARP and PD-L1 inhibition: a promising treatment option for relapsed small-cell lung cancer.聚（ADP-核糖）聚合酶（PARP）与程序性死亡受体 1 配体（PD-L1）联合抑制：复发性小细胞肺癌的一种有前景的治疗选择。
J Thorac Dis. 2024 Jun 30;16(6):4075-4078. doi: 10.21037/jtd-24-269. Epub 2024 Jun 25.
4
Immunotherapy-Related Cystitis: Case Report and Review of the Literature.免疫治疗相关膀胱炎：病例报告及文献综述
Onco Targets Ther. 2021 Jul 31;14:4321-4328. doi: 10.2147/OTT.S321965. eCollection 2021.
本文引用的文献
1
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.卡铂联合依托泊苷与拓扑替康二线治疗敏感复发性小细胞肺癌的疗效比较：一项开放标签、多中心、随机、III 期临床试验。
Lancet Oncol. 2020 Sep;21(9):1224-1233. doi: 10.1016/S1470-2045(20)30461-7.
2
Irinotecan, topotecan, paclitaxel or docetaxel for second-line treatment of small cell lung cancer: a single-center retrospective study of efficiency comparation and prognosis analysis.伊立替康、拓扑替康、紫杉醇或多西他赛用于小细胞肺癌二线治疗：一项单中心疗效比较及预后分析的回顾性研究
Transl Lung Cancer Res. 2019 Dec;8(6):829-837. doi: 10.21037/tlcr.2019.10.21.
3
Treatment patterns and survival outcomes for small-cell lung cancer patients - a Swedish single center cohort study.小细胞肺癌患者的治疗模式和生存结局 - 一项瑞典单中心队列研究。
Acta Oncol. 2020 Apr;59(4):388-394. doi: 10.1080/0284186X.2019.1711165. Epub 2020 Jan 7.
4
Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.纳武利尤单抗单药治疗和纳武利尤单抗联合伊匹单抗治疗复发性小细胞肺癌：CheckMate 032 随机队列研究结果。
J Thorac Oncol. 2020 Mar;15(3):426-435. doi: 10.1016/j.jtho.2019.10.004. Epub 2019 Oct 17.
5
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
6
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer.帕博利珠单抗联合紫杉醇治疗复发或难治性小细胞肺癌的 II 期研究。
Lung Cancer. 2019 Oct;136:122-128. doi: 10.1016/j.lungcan.2019.08.031. Epub 2019 Aug 29.
7
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.一线、二线和三线治疗广泛期小细胞肺癌 432 例患者的治疗和结局——前瞻性德国 TLK 队列研究的结果。
Lung Cancer. 2019 Apr;130:216-225. doi: 10.1016/j.lungcan.2019.02.026. Epub 2019 Feb 25.
8
Immunotherapy in extensive small cell lung cancer.广泛期小细胞肺癌的免疫治疗
Exp Hematol Oncol. 2019 Feb 4;8:5. doi: 10.1186/s40164-019-0129-x. eCollection 2019.
9
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial.抗程序性细胞死亡配体 1 阿特珠单抗或化疗作为小细胞肺癌二线治疗的随机非对照 II 期研究：IFCT-1603 试验结果。
J Thorac Oncol. 2019 May;14(5):903-913. doi: 10.1016/j.jtho.2019.01.008. Epub 2019 Jan 18.
10
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌。
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
Zotero 插件